<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176536</url>
  </required_header>
  <id_info>
    <org_study_id>1434-0002</org_study_id>
    <secondary_id>2019-003744-69</secondary_id>
    <nct_id>NCT04176536</nct_id>
  </id_info>
  <brief_title>A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to investigate the influence of moderate and severe renal&#xD;
      impairment on the pharmacokinetics of a single dose of BI 764198 in comparison to a group of&#xD;
      matched controls with normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 the last quantifiable data point)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 764198</intervention_name>
    <description>Capsules</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Despite of moderate and severe renal impairment (Group 1 and Group 2) male or female&#xD;
             subjects (at least 25% of each gender) according to the assessment of the&#xD;
             investigator, as based on a complete medical history including a physical examination,&#xD;
             vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG),&#xD;
             and clinical laboratory tests&#xD;
&#xD;
          -  Estimated Glomerular filtration rate (eGFR) based on Chronic kidney disease (CKD)-EPI&#xD;
             formula for Group 1 between 30 and 59 mL/min/1.73m², for Group 2 between 15 and 29&#xD;
             mL/min/1.73m² and for Group 3 ≥90 mL/min/1.73m²&#xD;
&#xD;
          -  Age of 18 to 79 years (inclusive)&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 34 kg/m^2 (inclusive)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          -  Male subjects, or female subjects who meet any of the following criteria from at least&#xD;
             30 days before the first administration of trial medication until 30 days after trial&#xD;
             completion:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. any of the following methods plus condom:&#xD;
                  implants, injectables, combined oral or vaginal contraceptives, intrauterine&#xD;
                  device&#xD;
&#xD;
               -  Sexually abstinent (defined as refraining from heterosexual intercourse during&#xD;
                  the entire period of risk)&#xD;
&#xD;
               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
          -  Surgically sterilised (including hysterectomy)&#xD;
&#xD;
             -- Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in&#xD;
             questionable cases a blood sample with levels of Follicle-stimulation hormone (FSH)&#xD;
             above 40 U/L and estradiol below 30 ng/L is confirmatory) Control subjects (Group 3)&#xD;
&#xD;
          -  Subjects who can be matched to renal impaired subjects from Group 1 and/or Group 2&#xD;
             based on gender, race, age (within ±10%) and BMI (within ±10%)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Control subjects:&#xD;
&#xD;
          -  Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR)&#xD;
             or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant&#xD;
             by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Estimated Glomerular filtration rate (eGFR) calculated by Chronic kidney disease&#xD;
             (CKD)-EPI formula &lt; 90 mL/min/1.73m²&#xD;
&#xD;
        Subjects with moderate and severe renal impairment:&#xD;
&#xD;
          -  Subject with significant diseases, in the opinion of the investigator, other than&#xD;
             moderate or severe renal impairment. A significant disease is defined as a disease&#xD;
             which is in the opinion of the investigator:&#xD;
&#xD;
               -  puts the subjects at risk by participating in the study&#xD;
&#xD;
               -  may influence the results of the study&#xD;
&#xD;
               -  may influence the subject's ability to participate in the study&#xD;
&#xD;
               -  is not in a stable condition Diabetic or hypertensive subjects can be entered in&#xD;
                  this trial if the disease is not significant according to those criteria.&#xD;
&#xD;
          -  Moderate and severe concurrent liver function impairment (e.g. due to hepatorenal&#xD;
             syndrome) or biliary obstruction&#xD;
&#xD;
          -  Clinically relevant laboratory abnormalities (except for renal function tests or&#xD;
             deviation of clinical laboratory values that are related to renal impairment)&#xD;
&#xD;
          -  eGFR calculated by CKD-EPI formula ≥60 mL/min/1.73m² and &lt; 30 mL/min/1.73m² for Group&#xD;
             1 and ≥30 mL/min/1.73m² and &lt; 15 mL/min/1.73m² for Group 2&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  Use of drugs within 30 days of planned administration of trial medication that might&#xD;
             reasonably influence the results of the trial (including drugs that cause QT/QTc&#xD;
             interval prolongation)&#xD;
&#xD;
          -  Intake of an investigational drug in another clinical trial within 30 days of planned&#xD;
             administration of investigational drug in the current trial, or longer if required by&#xD;
             local regulation, or within 5 half-lives of the investigational agent taken (whichever&#xD;
             is longer) or concurrent participation in another clinical trial in which&#xD;
             investigational drug is administered&#xD;
&#xD;
          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
          -  Inability to refrain from smoking on specified trial days&#xD;
&#xD;
          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for&#xD;
             males)&#xD;
&#xD;
          -  Drug abuse or positive drug screening&#xD;
&#xD;
          -  Blood donation of more than 100 mL within 30 days of planned administration of trial&#xD;
             medication or intended blood donation during the trial&#xD;
&#xD;
          -  Intention to perform excessive physical activities within one week prior to the&#xD;
             administration of trial medication or during the trial&#xD;
&#xD;
          -  Inability to comply with the dietary regimen of the trial site&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are&#xD;
             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)&#xD;
             or any other relevant ECG finding at screening&#xD;
&#xD;
          -  A history of additional risk factors for Torsade de Pointes (such as heart failure,&#xD;
             hypokalaemia, or family history of Long QT Syndrome)&#xD;
&#xD;
          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,&#xD;
             because the subject is not considered able to understand and comply with study&#xD;
             requirements, or has a condition that would not allow safe participation in the study&#xD;
&#xD;
        Female subjects will not be allowed to participate, if any of the following apply:&#xD;
&#xD;
          -  Positive pregnancy test, pregnancy, or plans to become pregnant within 30 days after&#xD;
             study completion&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
        Male subjects will not be allowed to participate, if any of the following apply:&#xD;
&#xD;
          -  Male subjects with WOCBP partner who are unwilling to use male contraception (condom&#xD;
             or sexual abstinence) from the first administration of trial medication until 30 days&#xD;
             after last administration of trial medication&#xD;
&#xD;
          -  positive test indicating an ongoing infection with SARS-CoV-2 and clinical symptoms&#xD;
             suggestive of the disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

